Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

392.44 -3.88 (-0.98%)

Delayed Quote Updated: 1:13 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says ↗

June 28, 2023

Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was...

Via Benzinga

Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 27, 2023

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.

Via Benzinga

2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street ↗

May 30, 2023

Recent moves to the upside could be the beginning of a much larger bull run.

Via The Motley Fool

Why Madrigal Pharmaceuticals Stock Is Marching Higher Today ↗

May 24, 2023

Two key tailwinds appear to be lifting the stock today.

Via The Motley Fool

Analyst Expectations for Madrigal Pharmaceuticals's Future ↗

May 16, 2023

Via Benzinga

Why Madrigal Pharmaceuticals Stock Is Slumping Today ↗

May 09, 2023

The biotech's shares briefly plunged following its 2023 Q1 earnings report.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

May 26, 2023

Via Benzinga

Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session

May 23, 2023

Via Investor Brand Network

Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug ↗

May 22, 2023

The FDA's advisors voted resoundingly against accelerated approval for obeticholic acid.

Via Investor's Business Daily

Why These 3 Nasdaq Stocks Buckled Today ↗

May 16, 2023

The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.

Via The Motley Fool

Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial ↗

May 16, 2023

Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in

Via Benzinga

Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/17 Morning Trading

March 17, 2023

Via Investor Brand Network

2 Surging Healthcare Stocks That Are Still Worth Buying ↗

February 23, 2023

These two NASH drugmakers have a lot of room to run.

Via The Motley Fool

Here's How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 Years ↗

January 09, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

April 28, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 27, 2023

Via Benzinga

3 Biotechs That Might Get Bought Out in 2023 ↗

April 26, 2023

Biotech is expected to be a hotbed of mergers and acquisitions this year.

Via The Motley Fool

Why Madrigal Pharmaceuticals Stock Gained 20% This Week ↗

April 20, 2023

Two key tailwinds fueled a surge in the biotech's share price this week.

Via The Motley Fool

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names ↗

April 20, 2023

Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is...

Via Benzinga

Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout ↗

April 18, 2023

Shares are closing in on a buy point after retaking their 50-day moving average.

Via Investor's Business Daily

Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session

April 18, 2023

Via Investor Brand Network

5 Best Stocks to Buy in April ↗

April 01, 2023

These powerful trends should yield stellar returns for investors in April and beyond.

Via The Motley Fool

Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run ↗

March 29, 2023

Viking Therapeutics stock might in the midst of a historic run.

Via The Motley Fool

Is Viking Therapeutics a Smart Buy on the Dip? ↗

March 27, 2023

The stock recently fell around 25% for reasons that had nothing to do with its lead program.

Via The Motley Fool

Want Diversified Upside in Biotechnology? Check out LABU

March 22, 2023

Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.

Via MarketBeat

Topics ETFs Stocks

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle ↗

March 10, 2023

Meanwhile, the company is facing a stout rival in the form of Madrigal Pharmaceuticals.

Via Investor's Business Daily

1 Incredible Growth Stock That Could Turn $200,000 Into $1 Million by 2030 ↗

March 09, 2023

This clinical-stage biopharma stock could harbor one of the best-selling drugs of all time.

Via The Motley Fool

3 Incredible Growth Stocks to Buy if the Market Dips ↗

March 02, 2023

These top growth stocks sport premium valuations for a very good reason.

Via The Motley Fool

3 Top Healthcare Stocks to Buy for January ↗

January 11, 2023

These healthcare stocks have a lot going for them in the new year.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.